Impact of expression of the uPA system in sarcomas.

Research paper by Helge H Taubert, Viktor V Magdolen, Matthias M Kotzsch

Indexed on: 06 Jun '13Published on: 06 Jun '13Published in: Biomarkers in medicine


The uPA system mainly comprises the urokinase-type plasminogen activator uPA, the cell-surface receptor uPA receptor and the inhibitor PAI-1. Its clinical and prognostic impact especially in breast cancer is well investigated. In this short report, we summarize the published data describing expression of uPA, PAI-1 and uPA receptor and their relevance to clinical and survival data in sarcomas underlining their impact as tumor biomarkers in this tumor type as well.